Synthroid vs Tirosint: Switching Between Levothyroxine Tablet and Gel Cap

Same Molecule, Different Delivery

Both Synthroid and Tirosint deliver levothyroxine sodium (T4) to replace or supplement what the thyroid gland does not produce on its own. The difference is the vehicle. Synthroid is a traditional compressed tablet containing lactose monohydrate, acacia, confectioner's sugar, magnesium stearate, povidone, talc, and FD&C dyes that vary by dose strength. Tirosint strips the formulation down to three inactive ingredients inside a soft gel shell.

This matters because levothyroxine is a narrow therapeutic index (NTI) drug. The American Thyroid Association (ATA) 2014 guidelines state that even small changes in absorption can shift TSH outside the target range [1]. Tablet excipients interact with gastric pH, food residue, and co-administered medications in ways the gel cap largely avoids.

The clinical question is not whether Tirosint "works better" in a vacuum. It is whether the gel cap formulation produces more consistent absorption for a given patient's GI environment. For most people with normal gut function taking their tablet correctly, the answer is no. For patients with absorption challenges, the answer may be different.

Absorption and Bioavailability Differences

Levothyroxine tablets require dissolution in gastric acid before the drug can be absorbed in the jejunum and upper ileum. Anything that raises gastric pH (proton pump inhibitors, H2 blockers), coats the intestinal wall (calcium carbonate, iron supplements), or speeds transit (short bowel, celiac disease, bariatric surgery) can reduce how much T4 reaches the bloodstream.

Tirosint bypasses the dissolution step. The T4 is already in liquid form inside the gel capsule. Vita et al. (Endocrine, 2014) studied patients with impaired gastric acid secretion and those taking PPIs who had persistent TSH elevation despite adequate tablet doses. After switching to the gel cap formulation at the same mcg dose, TSH normalized without dose increases in the majority of subjects [2]. The study confirmed that the liquid formulation's absorption was less dependent on gastric pH.

A pharmacokinetic study published in Thyroid showed that Tirosint achieved similar AUC values whether taken in fasting or fed states, whereas the tablet form showed reduced T4 absorption when taken with food [3]. This does not mean Tirosint eliminates the fasting requirement entirely, but the margin of error is wider.

One point is frequently overstated: Tirosint is not "better absorbed" in an absolute sense. In a healthy fasting patient with normal GI function and no interacting medications, both formulations deliver equivalent T4 to the bloodstream. The gel cap's advantage appears specifically when something interferes with tablet dissolution.

When Switching Makes Clinical Sense

Not every patient on Synthroid should switch to Tirosint. The ATA guidelines do not express a preference for one levothyroxine formulation over another in the general hypothyroid population [1]. The clinical scenarios where a switch is worth discussing fall into specific categories.

GI absorption impairment. Patients with celiac disease, inflammatory bowel disease, short bowel syndrome, or prior bariatric surgery (especially Roux-en-Y gastric bypass) often have erratic T4 absorption from tablets. A 2020 retrospective analysis in the Journal of the Endocrine Society found that post-bariatric patients required 20% to 48% higher tablet levothyroxine doses compared to non-surgical controls, and dose requirements were more stable after switching to a liquid or gel cap formulation [4].

Concurrent PPI use. Chronic proton pump inhibitor therapy raises gastric pH, which impairs tablet dissolution. Vita et al. demonstrated that switching these patients to Tirosint restored TSH control at the original dose [2]. This avoids the cycle of repeated dose escalation.

Lactose or dye sensitivity. Synthroid tablets contain lactose and synthetic dyes. Patients with true lactose intolerance or documented dye hypersensitivity have a straightforward reason to choose Tirosint.

Persistent TSH instability despite good adherence. Some patients report taking their tablet correctly, fasting, waiting 30 to 60 minutes before food or other medications, and still have TSH values that fluctuate visit to visit. If adherence has been genuinely verified and timing is confirmed, a formulation switch is a reasonable next step before escalating the dose.

Coffee before waiting period. A study in Thyroid (Benvenga et al., 2008) showed that coffee consumed shortly after tablet levothyroxine reduced intestinal absorption of T4 [5]. Patients unwilling or unable to delay coffee intake by 60 minutes after dosing may achieve more reliable absorption with the gel cap form.

How to Switch: Step by Step

The conversion is simple on paper. Use the same mcg dose. A patient on Synthroid 100 mcg daily switches to Tirosint 100 mcg daily. No loading dose. No taper.

The reason this works is that both products contain USP levothyroxine sodium and must meet the same FDA potency standards (95% to 105% of labeled content). The ATA recommends that whenever a patient switches between any levothyroxine products, including branded-to-branded, branded-to-generic, or formulation changes, TSH should be measured 6 to 8 weeks later [1].

Here is the practical protocol most endocrinologists follow:

1. Document the current stable dose and most recent TSH on the existing formulation.
2. Write the Tirosint prescription at the identical mcg strength.
3. Instruct the patient to take the gel cap on an empty stomach with water, same as the tablet (although the fasting window can be shorter with Tirosint, many clinicians recommend maintaining the same routine for consistency).
4. Recheck TSH and free T4 at 6 to 8 weeks.
5. Adjust dose by 12.5 to 25 mcg increments if TSH is outside target.

One practical note: Tirosint is available in 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg capsules. Synthroid offers a wider range of tablet strengths. If a patient is on an uncommon dose like 175 mcg, a combination of two Tirosint capsules may be needed, which adds cost.

Cost and Insurance Realities

This is where the conversation gets difficult. Tirosint costs substantially more than Synthroid, and Synthroid costs substantially more than generic levothyroxine tablets. According to GoodRx data from 2025, a 30-day supply of generic levothyroxine 100 mcg runs approximately $4 to $15 at most pharmacies. Synthroid at the same dose runs $40 to $70. Tirosint 100 mcg runs $80 to $150 without insurance.

Many insurance formularies classify Tirosint as a non-preferred brand, requiring prior authorization. The clinical documentation required typically includes evidence of therapeutic failure on tablet formulations or a documented malabsorption condition.

Dr. Victor Bernet, past president of the American Thyroid Association, has noted: "The gel cap formulation is a useful option for the right patient, but the cost differential means we reserve it for cases where tablet absorption is genuinely compromised, not as a first-line choice."

For patients without insurance coverage, IBSA (Tirosint's manufacturer) offers a patient assistance program and copay card. Some compounding pharmacies also prepare liquid levothyroxine at lower cost, although compounded preparations lack the same bioequivalence data.

Comparing Side Effects and Tolerability

Because the active drug is identical, the side-effect profile is the same. Levothyroxine side effects are almost always dose-related: palpitations, tremor, insomnia, heat intolerance, and diarrhea signal overreplacement, while fatigue, constipation, weight gain, and cold intolerance signal underreplacement.

The formulation-specific tolerability differences are about the inactive ingredients. Patients who experience GI upset, bloating, or allergic-type reactions on Synthroid tablets may be reacting to the lactose, acacia gum, or dyes. Switching to Tirosint eliminates these exposures.

A 2015 survey published in International Journal of Pharmaceutical Compounding found that among patients who self-reported intolerance to levothyroxine tablets, 78% reported symptom resolution after switching to either a gel cap or liquid formulation [6]. This is difficult to interpret rigorously because self-reported intolerance is subjective and the survey lacked a placebo arm. The signal is consistent enough that most thyroidologists consider it worth trying.

There are no head-to-head randomized controlled trials comparing Synthroid tablets directly to Tirosint gel caps for patient-reported outcomes like quality of life or symptom burden. The Vita et al. study focused on TSH normalization, not symptom scores [2].

Thyroid Medication Timing: Does the Gel Cap Buy You Flexibility?

The standard instruction for levothyroxine tablets is rigid: take on an empty stomach, first thing in the morning, with a full glass of water, then wait 30 to 60 minutes before eating or drinking anything other than water. Wait 4 hours before taking calcium or iron supplements.

The gel cap's reduced sensitivity to food and pH interference has led some clinicians to offer patients slightly more flexible dosing windows. A 2009 study in AACE Clinical Case Reports described patients who achieved stable TSH levels when taking Tirosint just 15 to 20 minutes before breakfast, rather than the standard 30 to 60 minute wait [7].

This flexibility is modest. Tirosint is not a "take with food" medication. The absorption advantage over tablets narrows the penalty for imperfect timing rather than eliminating timing requirements altogether.

For patients who struggle with the morning fasting window, bedtime dosing is another option supported by data for both formulations. A randomized crossover trial in Archives of Internal Medicine (Bolk et al., 2010) found that bedtime levothyroxine administration improved TSH and free T4 levels compared to morning dosing, likely because the overnight fast is naturally longer [8].

What the Guidelines Say

The ATA 2014 guidelines represent the most authoritative U.S. guidance on levothyroxine therapy [1]. Key points relevant to the Synthroid-versus-Tirosint comparison:

• Levothyroxine (any formulation) is the recommended treatment for hypothyroidism.
• The guidelines recognize that different levothyroxine products may not be bioequivalent despite containing the same labeled dose. TSH monitoring after any product switch is mandatory.
• The guidelines do not endorse one branded product over another. The choice between tablet, gel cap, and liquid formulations should be individualized.

The European Thyroid Association (ETA) published a 2021 position statement specifically addressing liquid and soft gel levothyroxine formulations, noting that they "may be preferred in patients with known or suspected malabsorption, those on medications that interfere with tablet dissolution, or those who cannot comply with strict fasting requirements" [9].

Neither guideline body calls Tirosint superior to Synthroid as a blanket statement. Both frame formulation choice as a clinical decision based on individual patient factors.

Switching Back: Tirosint to Synthroid

Some patients try Tirosint and return to tablets, usually because of cost. The same rules apply in reverse: convert mcg-for-mcg, recheck TSH at 6 to 8 weeks. If the original reason for switching was malabsorption, going back to the tablet may recreate the same absorption problems. In that case, addressing the underlying issue (stopping the PPI, treating celiac disease, optimizing bariatric supplement regimens) should accompany the switch back.

Patients who switched for lactose or dye sensitivity and want to return to a tablet form can consider Tirosint-SOL (the liquid solution from the same manufacturer) or dye-free generic levothyroxine tablets, which some manufacturers now offer in certain dose strengths.

Generic Levothyroxine Gel Caps

As of 2026, no AB-rated generic equivalent to Tirosint exists on the U.S. market. The gel cap manufacturing process is more complex than tablet compression, and IBSA holds patents on the formulation. This lack of generic competition is the primary reason Tirosint remains expensive relative to tablets.

Patients sometimes ask about levothyroxine liquid (Tirosint-SOL), which is also manufactured by IBSA. The liquid formulation shares Tirosint's absorption advantages and similarly minimal excipient list. Pricing is comparable to the gel cap. The liquid may be easier to dose in small increments for patients who need fine adjustments (e.g., pediatric dosing or TSH fine-tuning in elderly patients with cardiac disease).